A5023892647- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Inflammasome and immune disorders
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Neuroinflammation and Neurodegeneration Mechanisms
- Immune cells in cancer
- Immune responses and vaccinations
- Immunotherapy and Immune Responses
- Aging, Health, and Disability
- Frailty in Older Adults
- Dermatological and COVID-19 studies
- Chronic Disease Management Strategies
- Telomeres, Telomerase, and Senescence
- Immune Cell Function and Interaction
- Genetics, Aging, and Longevity in Model Organisms
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Center of Molecular Immunology (Cuba)
2020-2024
Universidad de Ciencias Médicas de la Habana
2023
Victoria School of Management
2020
Background: Lung injury and STAT1 deficit induce EGFR overexpression in SARS-CoV-2 infection. Patients & methods: A phase I/II trial was done to evaluate the safety preliminary effect of nimotuzumab, an anti-EGFR antibody, COVID-19 patients. received from one three infusions together with other drugs included national guideline. Results: 41 patients (31 severe 10 moderate) nimotuzumab. The median age 62 years main comorbidities were hypertension, diabetes cardiovascular disease. antibody...
Introduction Immunosenescence is a dynamic process, where both genetic and environmental factors account for the substantial inter-individual variability. This paper integrates all data on immunosenescence markers generated in our laboratory describes differences and/or similarities between individuals based their biological conditions (immunosenescence markers) associations with chronological age health status. Materials Methods The dataset consisted of immunological from healthy donors,...
Abstract Background Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around world has been placed. In Cuba, first case of was reported on March 11. Elderly with multiple comorbidities have most risky population. Although patients present a mild to moderate disease, some developed severe symptoms. One possible mechanisms underlying rapid disease progression is cytokine storm, in which interleukin (IL) -6 seems be major mediator. Itolizumab humanized recombinant...
Introduction: Centenarians are considered a model of successful aging. Cuba exhibits one the oldest populations in Latin America with more than two thousand centenarians. Methods: This study aimed to evaluate immune phenotype forty-three Cuban centenarians, their clinical characteristics such as comorbidities, frailty, body mass index, and some hemochemical parameters. Results: had normal indexes, relatively good health status, 21.95% them no comorbidities; 53.6% were classified frail, 7%...
In COVID-19, the inflammatory cytokine-release syndrome is associated with progression of disease. Itolizumab a monoclonal antibody that recognizes human CD6 expressed in activated T cells. The has shown to be safe and efficacious treatment moderate severe psoriasis. Its effect reduction pro-inflammatory cytokines release, including IFN-γ, IL-6 TNF-α. Here, we report outcome three critically ill COVID-19 patients treated itolizumab as part an expanded access protocol. was able reduce...
Lung cancer is the second cause of related deaths worldwide. Chemotherapy and immunotherapy represent current standard care for advanced NSCLC. Platinum-based chemotherapy expands late-differentiated T cell populations. Therefore, immune restoration after to adjuvate immunotherapeutic potential could be crucial. The aim this study was evaluate effect Biomodulina (BT), a thymic polypeptide fraction, on peripheral lymphocytes subpopulations in context disease. Additionally, whether these...
Background: In COVID-19, EGFR production is upregulated in the alveolar epithelial cells. overexpression further activates STAT-3 and increases lung pathology. The pathway also one of major nodes pulmonary fibrosis. Methods: Nimotuzumab, a humanized anti-EGFR antibody, was used to treat three patients with severe or moderate COVID-19. antibody administered combination other drugs included national COVID-19 protocol. Results: Nimotuzumab well tolerated. IL-6 decreased from first infusion....
Abstract Background : Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around world has been placed. In Cuba, first case of was reported on March 11. Elderly with multiple comorbidities have most risky population. Although patients present a mild to moderate disease, some developed severe symptoms. One possible mechanisms underlying rapid disease progression is cytokine storm, in which interleukin (IL) -6 seems be major mediator. Itolizumabis humanized...
Abstract Background : Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around world has been placed. In Cuba, first case of was reported on March 11. Elderly with multiple comorbidities have most risky population. Although patients present a mild to moderate disease, some developed severe symptoms. One possible mechanisms underlying rapid disease progression is cytokine storm, in which interleukin (IL) -6 seems be major mediator. Itolizumab humanized recombinant...
Aim: Currently, malignant diseases represent a health issue worldwide. Among these, lung cancer is of growing importance, due to its high incidence and mortality. Chemotherapy, one the most frequently used treatments, has shown ability induce accelerated immunosenescence in classic as well non-classic lymphocyte compartments, being less described latter. The immune restoration strategies have demonstrated their reverse exhaustion markers conventional subpopulations after chemotherapy....
Abstract Background : Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around world has been placed. In Cuba, first case of was reported on March 11. Elderly with multiple comorbidities have most risky population. Although patients present a mild to moderate disease, some developed severe symptoms. One possible mechanisms underlying rapid disease progression is cytokine storm, in which interleukin (IL) -6 seems be major mediator. Itolizumab humanized recombinant...